The effect of Epstein – Barr Virus Viremia on the Progression to Severe COVID-19
Abstract BackgroundCoronavirus disease 2019 (COVID-19) can reactivate several latent viruses. Epstein–Barr virus (EBV) is a latent virus that is frequently reactivated in patients with critical illnesses. Recently, a high incidence of viremia has been reported in patients with severe COVID-19. However, it is unclear whether EBV viremia is the result of the severity of COVID-19 or if it affects the severity of COVID-19. Therefore, we conducted a cohort study to evaluate the effects of EBV on the progression of COVID-19.MethodsWe compared the incidence of EBV viremia between the COVID-19 and non-COVID-19 groups. Simplified Acute Physiology Score (SAPS) II and lymphocyte subsets were analyzed in patients with COVID-19. We also observed that patients with COVID-19 with EBV viremia progressed to severe pneumonia more often than those without EBV viremia.ResultsTwo hundred and nine patients with COVID-19 were compared with the control (non-COVID-19) group. The incidence of EBV viremia was lower in the COVID-19 group than in the non-COVID-19 group (17.1% vs. 26.8%, P=0.034). In the subgroup analysis of the COVID-19 group, the EBV-positive group patients had more severe COVID-19 infection than the EBV-negative group (SAPS II, 22.3 vs. 17.4%; P=0.002). However, progression to moderate or severe pneumonia in patients with mild COVID-19 was rather high in the EBV-negative group (not statistically significant), contrary to our expectations.ConclusionsAlthough the severity of COVID-19 may affect EBV viremia, there is no evidence that EBV viremia is a factor that exacerbates pneumonia in patients with early COVID-19. The effect of EBV viremia on prolonged organizing pneumonia should be further studied..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
ResearchSquare.com - (2021) vom: 20. Apr. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Im, Jae Hyoung [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| doi: |
10.21203/rs.3.rs-432640/v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XRA03384030X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XRA03384030X | ||
| 003 | DE-627 | ||
| 005 | 20230429181936.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220113s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21203/rs.3.rs-432640/v1 |2 doi | |
| 035 | |a (DE-627)XRA03384030X | ||
| 035 | |a (ResearchSquare)10.21203/rs.3.rs-432640/v1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Im, Jae Hyoung |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a The effect of Epstein – Barr Virus Viremia on the Progression to Severe COVID-19 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract BackgroundCoronavirus disease 2019 (COVID-19) can reactivate several latent viruses. Epstein–Barr virus (EBV) is a latent virus that is frequently reactivated in patients with critical illnesses. Recently, a high incidence of viremia has been reported in patients with severe COVID-19. However, it is unclear whether EBV viremia is the result of the severity of COVID-19 or if it affects the severity of COVID-19. Therefore, we conducted a cohort study to evaluate the effects of EBV on the progression of COVID-19.MethodsWe compared the incidence of EBV viremia between the COVID-19 and non-COVID-19 groups. Simplified Acute Physiology Score (SAPS) II and lymphocyte subsets were analyzed in patients with COVID-19. We also observed that patients with COVID-19 with EBV viremia progressed to severe pneumonia more often than those without EBV viremia.ResultsTwo hundred and nine patients with COVID-19 were compared with the control (non-COVID-19) group. The incidence of EBV viremia was lower in the COVID-19 group than in the non-COVID-19 group (17.1% vs. 26.8%, P=0.034). In the subgroup analysis of the COVID-19 group, the EBV-positive group patients had more severe COVID-19 infection than the EBV-negative group (SAPS II, 22.3 vs. 17.4%; P=0.002). However, progression to moderate or severe pneumonia in patients with mild COVID-19 was rather high in the EBV-negative group (not statistically significant), contrary to our expectations.ConclusionsAlthough the severity of COVID-19 may affect EBV viremia, there is no evidence that EBV viremia is a factor that exacerbates pneumonia in patients with early COVID-19. The effect of EBV viremia on prolonged organizing pneumonia should be further studied. | ||
| 700 | 1 | |a Nahm, Chung Hyun |e verfasserin |4 aut | |
| 700 | 1 | |a Je, Young Soo |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Jin-Soo |e verfasserin |4 aut | |
| 700 | 1 | |a Kwon, Hea Yoon |e verfasserin |4 aut | |
| 700 | 1 | |a Chung, Moon-Hyun |e verfasserin |4 aut | |
| 700 | 1 | |a Jang, Ji-Hun |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Jeong Soo |e verfasserin |4 aut | |
| 700 | 1 | |a Lim, Jun Hyeok |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Mi Hwa |e verfasserin |4 aut | |
| 700 | 1 | |a Baek, Ji Hyeon |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ResearchSquare.com |g (2021) vom: 20. Apr. |
| 773 | 1 | 8 | |g year:2021 |g day:20 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-432640/v1 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XRA | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 20 |c 04 | ||
| 953 | |2 045F |a 570 | ||